HAVCR2 and neoplasm: Furthermore, TIM-3 inhibitors suppress IL-6/STAT3 signaling pathway activation in HCC cells, effectively inhibiting tumor proliferation and metastasis, which highlights their therapeutic potential against HCC [114].